AUPH
Price
$11.55
Change
-$0.00 (-0.00%)
Updated
Oct 17 closing price
Capitalization
1.52B
11 days until earnings call
DYAI
Price
$1.07
Change
+$0.02 (+1.90%)
Updated
Oct 17 closing price
Capitalization
38.72M
17 days until earnings call
Interact to see
Advertisement

AUPH vs DYAI

Header iconAUPH vs DYAI Comparison
Open Charts AUPH vs DYAIBanner chart's image
Aurinia Pharmaceuticals
Price$11.55
Change-$0.00 (-0.00%)
Volume$971.6K
Capitalization1.52B
Dyadic International
Price$1.07
Change+$0.02 (+1.90%)
Volume$43.49K
Capitalization38.72M
AUPH vs DYAI Comparison Chart in %
AUPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DYAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AUPH vs. DYAI commentary
Oct 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AUPH is a Hold and DYAI is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 19, 2025
Stock price -- (AUPH: $11.55 vs. DYAI: $1.07)
Brand notoriety: AUPH and DYAI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AUPH: 58% vs. DYAI: 34%
Market capitalization -- AUPH: $1.52B vs. DYAI: $38.72M
AUPH [@Biotechnology] is valued at $1.52B. DYAI’s [@Biotechnology] market capitalization is $38.72M. The market cap for tickers in the [@Biotechnology] industry ranges from $106.87B to $0. The average market capitalization across the [@Biotechnology] industry is $2.06B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AUPH’s FA Score shows that 0 FA rating(s) are green whileDYAI’s FA Score has 0 green FA rating(s).

  • AUPH’s FA Score: 0 green, 5 red.
  • DYAI’s FA Score: 0 green, 5 red.
According to our system of comparison, AUPH is a better buy in the long-term than DYAI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AUPH’s TA Score shows that 6 TA indicator(s) are bullish while DYAI’s TA Score has 4 bullish TA indicator(s).

  • AUPH’s TA Score: 6 bullish, 3 bearish.
  • DYAI’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, AUPH is a better buy in the short-term than DYAI.

Price Growth

AUPH (@Biotechnology) experienced а +2.48% price change this week, while DYAI (@Biotechnology) price change was +1.90% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.56%. For the same industry, the average monthly price growth was +15.88%, and the average quarterly price growth was +79.09%.

Reported Earning Dates

AUPH is expected to report earnings on Oct 30, 2025.

DYAI is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+1.56% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
AUPH($1.52B) has a higher market cap than DYAI($38.7M). AUPH YTD gains are higher at: 28.619 vs. DYAI (-38.857). AUPH has higher annual earnings (EBITDA): 86.5M vs. DYAI (-5.09M). AUPH has more cash in the bank: 315M vs. DYAI (4.98M). DYAI has less debt than AUPH: DYAI (5.06M) vs AUPH (81.8M). AUPH has higher revenues than DYAI: AUPH (260M) vs DYAI (3.42M).
AUPHDYAIAUPH / DYAI
Capitalization1.52B38.7M3,928%
EBITDA86.5M-5.09M-1,698%
Gain YTD28.619-38.857-74%
P/E Ratio26.86N/A-
Revenue260M3.42M7,600%
Total Cash315M4.98M6,321%
Total Debt81.8M5.06M1,615%
FUNDAMENTALS RATINGS
AUPH vs DYAI: Fundamental Ratings
AUPH
DYAI
OUTLOOK RATING
1..100
2191
VALUATION
overvalued / fair valued / undervalued
1..100
74
Overvalued
91
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
50100
PRICE GROWTH RATING
1..100
4254
P/E GROWTH RATING
1..100
10064
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AUPH's Valuation (74) in the Biotechnology industry is in the same range as DYAI (91). This means that AUPH’s stock grew similarly to DYAI’s over the last 12 months.

AUPH's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as DYAI (100). This means that AUPH’s stock grew similarly to DYAI’s over the last 12 months.

AUPH's SMR Rating (50) in the Biotechnology industry is somewhat better than the same rating for DYAI (100). This means that AUPH’s stock grew somewhat faster than DYAI’s over the last 12 months.

AUPH's Price Growth Rating (42) in the Biotechnology industry is in the same range as DYAI (54). This means that AUPH’s stock grew similarly to DYAI’s over the last 12 months.

DYAI's P/E Growth Rating (64) in the Biotechnology industry is somewhat better than the same rating for AUPH (100). This means that DYAI’s stock grew somewhat faster than AUPH’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AUPHDYAI
RSI
ODDS (%)
Bullish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
84%
Momentum
ODDS (%)
Bullish Trend 3 days ago
85%
Bearish Trend 3 days ago
87%
MACD
ODDS (%)
N/A
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
81%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
84%
Bullish Trend 3 days ago
77%
Advances
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 3 days ago
81%
Declines
ODDS (%)
Bearish Trend 7 days ago
82%
Bearish Trend 5 days ago
85%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
85%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
86%
Bullish Trend 3 days ago
74%
View a ticker or compare two or three
Interact to see
Advertisement
AUPH
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
DYAI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYNVX172.891.32
+0.77%
Rydex Nova Inv
CDOZX41.180.28
+0.68%
Columbia Dividend Opportunity Inst
CLGRX75.690.29
+0.38%
Calvert US Large Cap Growth Rspnb Idx R6
BIICX10.610.01
+0.09%
BlackRock Multi-Asset Income Instl
EICGX19.19-0.02
-0.10%
Eaton Vance China Equity I

AUPH and

Correlation & Price change

A.I.dvisor indicates that over the last year, AUPH has been loosely correlated with JSPR. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if AUPH jumps, then JSPR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AUPH
1D Price
Change %
AUPH100%
N/A
JSPR - AUPH
44%
Loosely correlated
-1.21%
MLTX - AUPH
41%
Loosely correlated
-2.77%
VCYT - AUPH
39%
Loosely correlated
+0.06%
KALA - AUPH
38%
Loosely correlated
-5.07%
LRMR - AUPH
38%
Loosely correlated
-1.41%
More

DYAI and

Correlation & Price change

A.I.dvisor tells us that DYAI and MDGL have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that DYAI and MDGL's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DYAI
1D Price
Change %
DYAI100%
+1.90%
MDGL - DYAI
29%
Poorly correlated
-0.73%
FATE - DYAI
28%
Poorly correlated
-4.55%
TAOX - DYAI
27%
Poorly correlated
-6.59%
QSI - DYAI
25%
Poorly correlated
-10.24%
AUPH - DYAI
24%
Poorly correlated
N/A
More